The increase resulted primarily from expenses associated with AcelRx’s operation as a public organization. December 31 For the year finished, 2011, AcelRx reported a net loss of $20.1 million, or $1.16 per share, compared with a net loss of $14.3 million, or $21.84 per talk about, for the same period this year 2010. As of December 31, 2011, AcelRx had cash, cash equivalents and investments of $35.8 million, in comparison to $32.0 million at September 30, 2011 and $3.at December 31 7 million, 2010.9 million.0 million secured loan agreement with Hercules Technology Development Capital, or Hercules.0 million in the first tranche of the loan and, in 2011 December, AcelRx drew down the second $10.0 million tranche of the loan. ‘During the last one fourth of 2011 and in to the first quarter of 2012, AcelRx finished system verification testing, software validation screening and reprocessing validation examining of our ARX-01 device, furthermore to filing a fresh IND for our ARX-04 product candidate.The independent academic statistical center also performed all analyses for this article and provided the composing group with unrestricted usage of the data. The manuscript was made by the main investigator and subsequently revised and edited by all of the authors. All the authors made a decision to submit the article for publication and assume responsibility for the accuracy and completeness of the reported data. Study People Patients with type 2 diabetes, chronic kidney disease , and a transferrin saturation of 15 percent or more were qualified to receive enrollment. Patients with any of the following elements were excluded: uncontrolled hypertension; previous kidney transplantation or scheduled receipt of a kidney transplant from a living related donor; current use of intravenous antibiotics, chemotherapy, or radiation therapy; cancers ; diagnosed human immunodeficiency virus infection; active bleeding; a hematologic disease; or pregnancy.